4/2
10:14 am
nbtx
Nanobiotix (NBTX) had its price target raised by Guggenheim from $26.00 to $36.00. They now have a "buy" rating on the stock.
Low
Report
Nanobiotix (NBTX) had its price target raised by Guggenheim from $26.00 to $36.00. They now have a "buy" rating on the stock.
4/1
02:06 pm
nbtx
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
4/1
11:35 am
nbtx
Nanobiotix H2 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Nanobiotix H2 Earnings Call Highlights [Yahoo! Finance]
3/31
04:30 pm
nbtx
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results [TheStreet.com]
High
Report
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results [TheStreet.com]
3/31
04:22 pm
nbtx
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results [Yahoo! Finance]
3/31
04:21 pm
nbtx
Nanobiotix GAAP EPS of -€0.50, revenue of €29.6M [Seeking Alpha]
High
Report
Nanobiotix GAAP EPS of -€0.50, revenue of €29.6M [Seeking Alpha]
3/31
04:15 pm
nbtx
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
High
Report
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
3/30
02:39 am
nbtx
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer [Yahoo! Finance]
Low
Report
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer [Yahoo! Finance]
3/30
02:30 am
nbtx
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Low
Report
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
3/26
04:15 pm
nbtx
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Medium
Report
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
3/25
10:11 am
nbtx
NANOBIOTIX Statement Regarding Recent Media Speculation
Low
Report
NANOBIOTIX Statement Regarding Recent Media Speculation
3/12
04:15 pm
nbtx
Voting Rights and Shares Capital of the Company
Medium
Report
Voting Rights and Shares Capital of the Company
3/12
11:07 am
nbtx
Nanobiotix (NBTX) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Nanobiotix (NBTX) had its "buy" rating reaffirmed by TD Cowen.
2/25
04:15 pm
nbtx
NANOBIOTIX to Participate in Investor Conferences in March
Medium
Report
NANOBIOTIX to Participate in Investor Conferences in March
2/17
04:15 pm
nbtx
Voting Rights and Shares Capital of the Company
Low
Report
Voting Rights and Shares Capital of the Company
2/6
09:47 am
nbtx
Nanobiotix (NASDAQ:NBTX) had its price target raised by analysts at Guggenheim from $8.00 to $26.00. They now have a "buy" rating on the stock.
Low
Report
Nanobiotix (NASDAQ:NBTX) had its price target raised by analysts at Guggenheim from $8.00 to $26.00. They now have a "buy" rating on the stock.
2/6
07:07 am
nbtx
Nanobiotix (NASDAQ:NBTX) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Low
Report
Nanobiotix (NASDAQ:NBTX) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
1/13
04:15 pm
nbtx
Voting Rights and Shares Capital of the Company
Low
Report
Voting Rights and Shares Capital of the Company